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Intracranial atherosclerotic disease (ICAD) accounts for 33–50% of all ischemic strokes
in the Asian population (1) and represents an important public health issue in China. The
results of the SAMMPRIS trial alarmed most experienced interventionalists in China for
two reasons. Firstly, the high complication rate in the stenting arm (20% the first year)
was higher than expected. Secondly, the recurrent stroke rate in the aggressive medical
treatment arm at 12.2% during the first year was unacceptably high, not to mention the
fact that such tight vascular risk factor control is difficult to achieve for many patients in
real life clinical experience, at least in China. The experience of treating ICAD in China,
gained over the last two decades, is very rich and promising. We intend to highlight these
past experiences and address future trials and trends in China. We will also address our
criticism of the SAMMPRIS trial design in order to better design a future trial.
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INTRACRANIAL STENTING FOR ICAD IN CHINA BEFORE
SAMMPRIS
The warfarin–aspirin symptomatic intracranial disease (WASID)
study showed that the role of medical therapy for intracranial
atherosclerosis (≥70%) is less effective, with the 1-year risk of
ischemic stroke remaining as high as 23% in patients who pre-
sented with stroke and 14% in patients who presented with tran-
sient ischemic attack (TIA) (2). Inspired by experience from the
treatment of the coronary artery disease, Chinese doctors began
treating patients with symptomatic intracranial artery stenosis
refractory to medical therapy with endovascular treatment since
the 1990s. The devices initially used were the coronary bal-
loons Magellan (Balt Co., Montmorency, France) and SeQuent (B.
Braun, Melsungen, Germany). Different stents including Coroflex
or Coroflex Blue (B. Braun, Melsungen, Germany), BiodivYsio
(Biocompatibles Ltd., Farnham, UK), S660 (AVE, Galway, Ireland),
and Firebird (MicroPort, Shanghai, China) were also used. Initial
reports were all single-center, self-reported studies, with varying
degree of success (96.46–97.6%) and low complication rates (4.42–
10%). When examined together, these studies included a total
of 528 patients (3–9), which constituted a rich database. When
compared with the expected natural history of the disease, the
consensus at that time was that these results supported the use of
the coronary stents as a mean for stroke prevention in patients
with intracranial atherosclerotic disease (ICAD).
With the dramatic increase of new cases, new devices specif-
ically designed for ICAD were developed. The Wingspan stent
system (Stryker, Kalamazoo, MI, USA) was the first commercially
available device since 2005 (10) and was introduced to China after
approval by the State Food and Drug Administration (SFDA) in
2007 (11). The Apollo balloon-mounted stent (MicroPort, Shang-
hai, China) was also approved by the SFDA the following year.
Since then, a series of registries followed their introduction to the
market, showing promising results for both the Wingspan and
Apollo stent systems (11, 12).
The current Chinese experience was summarized best in the
last Tiantan International Stroke Conference (TISC). A poll analy-
sis was presented on 1372 treated lesions between March 2005
and November 2011 using different devices (13). The distri-
bution of these lesions was as follows: 91 (7%) at the distal
internal carotid artery (ICA), 795 (58%) at the M1 segment
of the middle cerebral artery (MCA), 239 (17%) at the basi-
lar artery (BA), and 247 (18%) at the intracranial vertebral
artery (VA). Devices used included 323 coronary stents, 109 spe-
cially made intracranial balloon-mounted stents (Apollo), 638
Wingspan stents, and 38 cases of balloon angioplasties alone. The
success rate was promising with an average rate of 96% (92–
100%). The complication rate within 30 days was 8% (from 3.2
to 14.8%) (13).
We also independently reported our prospective registry
focused on symptomatic MCA stenosis, which demonstrated a
relatively high 1-year complication rate of 19.4%, compared to
the medical group of 17.6% (p= 0.85) (14). This result was very
similar to the later published SAMMPRIS study. Then, the general
consensus was that stenting is feasible, but its effectiveness at pre-
venting recurrent stroke with high grade symptomatic intracranial
stenosis still needed validation (7, 9, 10, 12, 13, 15).
SINCE SAMMPRIS
The publication of the SAMMPRIS (16) results, the first and only
prospective randomized trial to date, demonstrated high compli-
cation rates in the first 30 days following the Wingspan stenting in
one arm and lower than expected stroke risk in the aggressive med-
ical treatment (AMT) arm. This changed the accepted belief of the
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efficacy of intracranial stenting as a measure of stroke prevention,
and there is no reason to believe that a similar prospective trial
using the same device will have different results in China. Based
on the results, it is estimated that for intracranial stenting to remain
a promising measure for stroke prevention in these patients, the
peri-procedural complication rate within the first 30 days needs to
be<4% (7, 13). From our personal experience, and reviewing the
above highlighted Chinese experience, we believe that in order for
us to obtain such a low complication rate we need to enact a few
important changes. Firstly, a different patient selection criterion
should be employed. Secondly, a more complex treatment strategy
needs to be adopted (not all vessels or lesions are the same). Finally,
we need a better device than the Wingspan stent system (7).
The most obvious conclusion of SAMMPRIS is that the device
exclusively used (the Wingspan system) is not well suited for
intracranial stenting. We can speculate as to why the Wingspan
system ended up not being suitable for intracranial stenting, such
as the need for two steps (angioplasty then stenting) or the low
radial force of the stent making its opposition to the arterial wall
very limited, which has a tendency to encourage platelet aggrega-
tion and clot formation beneath the stent (17, 18). Besides the
stent itself, we believe that there was another shortcoming in
the trial design (19). Dissection following angioplasty has been
shown in a prospective registry to predict a higher stroke rate
in the peri-procedural period (20, 21). Since the slow inflation
technique of the angioplasty balloon was not included in the
trial protocol, and no angiogram following the angioplasty was
obtained prior to the stent placement, we can speculate that some
of the complications in SAMMPRIS were due to unaccounted
dissections caused by suboptimal angioplasty technique (7, 13,
17, 19). Secondly, in SAMMPRIS all the vessels were grouped
together without distinction between vessels with perforators (BA,
MCA) and those without perforators (VA, ICA), despite their
known different complication rates (20, 21). Thirdly, the SAMM-
PRIS protocol did not take into account the Mori classification,
yet there are numerous papers showing that lesions with dif-
ferent characteristics as classified by Mori carry different risks
during intracranial endovascular revascularization (IER) (20–26).
However, we still believe that SAMMPRIS was an important study
because at least it forced us to examine the question: how safe
is IER?
Building on prior literature, future trials need to take into
account the following points:
1. Improve patient selection: which group of patients will most
likely benefit from IER? It is suggested that patients with poor
collaterals stand a higher chance of benefit from IER than
patients with excellent collaterals (22). Poor collateral circu-
lation is determined as ≥40% decrease in cerebral blood flow
(CBF) at the stenotic arterial territory compared to CBF at the
reference area by CT or MRI perfusion (reference area being
defined as the contralateral hemisphere for anterior circulation
lesions or anterior circulation territory for posterior circulation
lesions); or a ASITN/SIR collateral flow grading system score
<3 as confirmed by diagnostic cerebral angiogram (2–26).
2. Improve device selection: we believe that different lesions
respond better to different devices.
a. For Mori A lesions with straightforward arterial access, the
balloon-mounted stent is our first choice, since no exchange
maneuver is needed and requires shorter procedural time
(3, 27–29).
b. For Mori B or C lesions with tortuous arterial access, or
lesions with a significant mismatch in the diameter between
the proximal and distal segment, the gateway balloon plus
Wingspan stent system is preferred because it is more flex-
ible compared to the balloon-mounted stent system (6–12,
28, 29).
c. For lesions near the perforator vessels (the mid-basilar artery
and distal M1 segment), lesions with tortuous arterial access
and Mori A classification, or lesions in a target vessel with
small diameter (<2.5 mm), angioplasty alone is simpler and
safer than stent implantation (28).
STUDIES IN CHINA SINCE SAMMPRIS
We recently published our new, prospective, single-center study
applying the aforementioned criteria (28). Between November
2011 and October 2012, 158 patients were enrolled into the study
Table 1 |The efficacy endpoints of different therapy groups.
BS group n=81 AG group n=39 AS group n=38 Total n=158 p
Primary endpoints
Successful PTAS, n (%) 79 (97.5) 35 (89.7) 38 (100.0) 152 (96.2) 0.042
Secondary endpoints
Any stroke or death 4 (4.9) 0 (0.0) 3 (7.9) 7 (4.4) 0.231
Any ischemic stroke 4 (4.9) 0 (0.0) 2 (5.3) 6 (3.8) 0.359
Any hemorrhagic stroke 0 (0.0) 0 (0.0) 1 (2.4) 1 (0.6) 0.204
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) –
MI 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) –
SAE 0 (0.0) 0 (0.0) 1 (2.4) 0 (0.6) 0.204
mRS≥3 2 (2.5) 0 (0.0) 2 (5.3) 4 (2.5) 0.339
BS group, balloon-mounted stent group; AG group, angioplasty group; AS group, angioplasty plus self-expanding stent group; MI, myocardial infarction; mRS, modified
Rankin scale; PTAS, percutaneous transluminal angioplasty and stenting; SAE, serious adverse even (28).
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and were divided into 3 groups: balloon-mounted stents (BS)
group (81 patients, some patients were treated first with gate-
way balloon and then with the Apollo stent), angioplasty alone
(AG) group (39 patients), and balloon angioplasty and Wingspan
stenting (AS) group (38 patients). The primary endpoints were
successful procedural rate and any vascular event within 30 days.
Overall technical success rate was 96% (152/158). Intracranial
stenting was successful in 97.5% (79/81) of patients in BS group,
100% (38/38) in AS group, and 89.7% (35/39) in AG group with
significant differences between the three groups (p= 0.042). The
30-day composite stroke or death rate was 4.4% (7/158). Any
stroke or death rate within 30 days in the BS group was 4.9%,
in AS group was 7.9%, and 0% in angioplasty AG group (see
Table 1). In this study, 59% of angioplasty cases needed secondary
stenting due to large dissection. These results, especially in the
angioplasty arm, are seemly very encouraging and point the merit
of our IER strategy; the primary outcome was not satisfying and
more than 50% require secondary stenting. There are more works
we should do.
Currently, there are two ongoing multicenter clinical trials
supported by both government agencies and medical device com-
panies: Wingspan Stenting for Symptomatic Intracranial Artery
Stenosis Registry study in China (WIRE-CHINA) and Apollo
Balloon-Mounted Stent for Symptomatic Intracranial Artery
Stenosis Registry study in China (AIRE-CHINA) (7, 13). These
studies will be carried out in more than 20 centers. The pri-
mary objective is to evaluate the safety of intravascular stenting
during the 30-day perioperative period in patients with sympto-
matic intracranial artery stenosis in the Chinese population using
a specific device. Their results are eagerly awaited.
CONCLUSION
In patients with symptomatic intracranial atherosclerotic lesion,
complex treatment strategy is needed. Different patients have dif-
ferent risk factors and indications, while different lesions respond
better to different devices. Future trials are needed and we are very
optimistic about their final outcome.
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